Polypid Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
~$11
Valuation models combined (2)
Base case. Range ~$1.6–$15. Weighted average of 2 models (justified price-to-book, forward price-to-sales vs peers).
Price vs value
No Buy/Hold/Sell rating is issued: limited reported history: available models are shown without a Buy/Hold/Sell rating.
Polypid Ltd. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds19 adding, 6 cuttingOf 5 active managers that changed their stake, 3 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Share count rising (dilution): Diluted shares outstanding rose 176.5% year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Polypid Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 176.5% in a year.
Latest results
- Earnings per share
- -$0.35 against an average estimate of -$0.38: beat by 7.3%
- Next report
- November 11, 2026; average EPS estimate $0.39
Price chart
- 1 day+1.6%
- 1 week-4.6%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-2.09
Growth
- Share count change
- +176.5%
Cash
- Free cash flow (TTM)
- -$28.1M
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for PYPD from the sources we follow. See filings →
Valuation models
We value Polypid Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: no revenue, margin or share count to start from |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | ~$15 ~$13–$18 | Included |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$1.6 ~$1.7–$6.3 | Included, half weight |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | ~$11 ~$1.6–$15 | 2 models |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Polypid Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 11, 2026, before the open. Analysts expect revenue of $18m and EPS of $0.39 (range −$0.41 to $0.96) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.61 | +71% | $21m | 0% |
| Next | −$1.05 | −72% | $10m | −54% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −28.3% on 90 days ago. In the last 30 days, 1 analyst raised Polypid Ltd.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.85 | −$1.11 |
| 60 days ago | −$0.89 | −$1.23 |
| 30 days ago | −$0.89 | −$1.23 |
| 7 days ago | −$0.89 | −$1.23 |
| Now | −$0.61 | −$1.05 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.38 | −$0.35 | +7.3% |
| Mar 2026 | −$0.43 | −$0.35 | +19.2% |
| Dec 2025 | −$0.33 | −$0.41 | −24.2% |
| Sept 2025 | −$0.52 | −$0.37 | +29.2% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 1.5% of tradable shares
- Days to cover
- 2.56 at average volume
- Short interest, 1 month
- +73% to October 15, 2026
- Held by institutions
- 35% of shares
- Held by insiders
- 12.3% of shares
- Employees
- 69 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities $15m of assets due within a year against $8m of liabilities due within a year.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Interest not separately reported. Not assessable.
Dividends, buybacks and capital spending
- Diluted share count
- +176.5%
- year over year
Who owns it
Funds buying and selling- Reported value
- $16.7M
- Institutions reporting
- 33
- Shares held vs prior quarter
- ▲ 5.2%
- Positions opened / closed
- 14 / 0
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Aigh Capital Management LLC | $7.6M | 1.5M | 45.9% | ▼ 5.6% |
| Rosalind Advisors, Inc. | $2M | 389K | 11.9% | ▼ 34.9% |
| Dafna Capital Management LLC | $1.1M | 208K | 6.3% | 0.0% |
| Morgan Stanley | $625,531 | 123K | 3.8% | ▼ 30.4% |
| Renaissance Technologies LLC | $592,425 | 117K | 3.6% | ▲ 527.1% |
| Marshall Wace, LLP | $584,273 | 115K | 3.5% | New |
| ADAR1 Capital Management, LLC | $528,066 | 104K | 3.2% | 0.0% |
| Symmetry Peak Management LLC | $512,475 | 101K | 3.1% | ▲ 15.7% |
| J. Goldman & Co LP | $503,850 | 99K | 3.0% | ▼ 33.7% |
| Jane Street Group, LLC | $422,280 | 83K | 2.5% | ▲ 284.1% |
| Quadrature Capital Ltd | $360,370 | 71K | 2.2% | New |
| Connective Capital Management, LLC | $343,408 | 68K | 2.1% | New |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Polypid Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Polypid Ltd. in brief
- What does Polypid Ltd. do?
- Polypid Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Polypid Ltd.'s stock ticker?
- Polypid Ltd. trades under the ticker PYPD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Polypid Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Aigh Capital Management LLC, Rosalind Advisors, Inc. and Dafna Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- When is Polypid Ltd.'s next earnings date?
- Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Polypid Ltd. announces its own schedule.
Follow research on Polypid Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.